RE:RE:A lot of pumpers on this board...RockLobster1 wrote: one thing to keep in mind about share issue is that it matters who you sell to and why. A well placed PP to institutions is an advantage, vs. the usual penny mining stock that issues massive paper with warrants just to keep the lights on and salaries going...
Any news shares will be done for strategic reasons, not desperation, and it will help to have institutions holding and backing us.
a historic day for IMV, will be volatile but a huge step.
I get some uncertainty around this, the immediate response is always to go to "dilution" but you have to consider the potential to add value. It opens the possibility of greater coverage in the US, without that the Nasdaq listing might have limited impact. Lets not forget, clinical activities are expensive, they may actually use the cash to do more work (imagine that!). They certainly have been signalling more intense clinical work for the future, this would allow that to happen unhindered. I guess biotech have two major options.
1) Sign deals early with large partners that gets them to cover much of the development costs but hands over much of the value.
or
2) Raise capital, pay for development yourself and retain more of the end value.
I think IMV had already said they dont like the first option, that makes this move somewhat inevitable.
I'm putting this in the catogory of 'necessary evil". How people want to respond to that in terms of their investment strategy is up to them.